Sixty-six derivatives of spiramycin I and neospiramycin I were synthesized and evaluated by four parameters, MIC, affinity to ribosomes (ID B0 ), therapeutic effect in mice and retention time in HPLC. Among the derivatives, 3,3",4*-tri-0-propionyland 3,4"-di-O-acetyl-3"-O-butyrylspiramycin I showed the highest therapeutic effect which was superior to acetylspiramycin. Structure activity relationships of spiramycins are discussed.
Introduction
Spiramycin (Pinnert-Sindico et al., 1955 ) is a complex of 16-membered macrolide antibiotics active against Gram-positive bacteria, mycoplasmas and toxoplasmas. Its acetyl derivative in addition to spiramycin is used clinically. Spiramycin contains three major components, I (3-OH), II (3-0-acetyl) , III (3-0-propionyl) . The structure and absolute configuration of spiramycin was determined by Omura et al. (1969) by comparison with the aglycone moiety of leucomycin A 3 . Spiramycin consists of four structural fragments: two amino-sugars, mycaminose and forosamine; one neutral sugar, mycarose: and a 16-membered lactone, platenolide. Neospiramycin is a demycarosyl derivative of spiramycin, prepared by the mild acid hydrolysis of spiramycin (Takahira, 1970) .
The chemical modification of macrolide antibiotics such as leucomycin (Sakakibara et al., 1981) , maridomycin (Harada et al., 1973) and tylosin type antibiotics, have been reported (Matsubara et al., 1982; Tsuchiya et al., 1982) . However, few reports of the chemical modification of spiramycin have been published, with the exception of acylation and hydrogenation (Takahira, 1970) . As spiramycin is only one 16-membered macrolide antibiotic which has an amino sugar, forosamine, at the 9-position, it appears to be differentiated from the other 16-membered macrolides in chemical reactivity and antimicrobial activity.
In this paper we describe the evaluation of the various derivatives by determination of MIC, affinity to ribosomes (ID 50 ), retention time on HPLC and ED 50 (or survival percentage), and the structure activity relationships of spiramycin.
Materials and methods

Preparation of derivatives of spiramycin I and neospiramycin I
Each derivative was synthesized from spiramycin I via each key intermediate described below (details of the synthesis will be published elsewhere).
4"-0-Sulphonyl (1 to 7) and 4"-O-alkylspiramycin I (8 to 11, Table I ) were synthesized 1 via 2'-0-acetylspiramycin I 3,18-(O-t-butyldimethylsilyl) acetal by sulphonylation and alkylation, and 3",4"-di-O-acylspiramycin I (12 to 25, Table II) were also synthesized via the same intermediate by 4"-0-acylation and 4" -• 3" acyl migration. 3,3",4"-Tri-0-acylspiramycin I (26 to 34, Table II) were prepared by selective acylation of spiramycin I and 4" -* 3" acyl migration. 3'-De-^V-methylspiramycin I, 4"'-de-A^-methylspiramycin I and their derivatives (35 to 44, Table III) were synthesized via 2'-O-acetyl-4"-O-(f-butyldimethylsilyl) spiramycin I 3,18-(0-f-butyldimethylsilyl) acetal through Nbromination as a key reaction. 3 and/or 4'-acetal derivatives of neospiramycin I (45 to 60, Table IV ) (Sano et al., 1983) were synthesized via 2'-O-acetylneospiramycin I, which were further converted to 4'-deoxy derivatives and their 12Z isomers (61 to 66, Table V ) by 4'-O-sulphonylation and reductive dechlorination.
Chimeramycins A and B
Chimeramycins A (67) and B (68) (Table VI) which are constructed with the aglycone of tylosin and the sugars of spiramycin, were prepared from protylonolide by hybrid biosynthesis (Omura et al., 1980) using the spiramycin-producing strain, Streptomyces ambofaciens 154) and cerulenin, an inhibitor of de novo synthesis of the aglycone moiety.
MIC determination
The MIC of each derivative against various bacteria were determined by the agar dilution method using heart infusion agar (pH 7-0).
ID S0 for the binding to ribosomes
The 50% inhibition dose (ID 50 ) of the derivatives for [10, 11, 12, H]tetrahydroleucomycin A 3 binding to Escherichia coli ribosomes were determined as described previously .
Retention time on HPLC
HPLC was performed on a reverse phase silica gel column (Merck Lichrosorb RP-8, 4 x 250 mm) with CH 3 CN :02 M NaH 2 PO 4 = 1:2 as a solvent system. Retention time was recorded at 1 ml/min of flow rate with a ultraviolet monitor (231 ran).
Therapeutic effect in experimental mouse-protection tests
The therapeutic effect was represented by ED 50 or survival percentage. Mice (ddY; <$: 19 + 1 g, 5 mice a group) were infected intraperitoneally with Staphylococcus aureus Smith or Streptococcus pneumoniae Type HI. Compounds were suspended in 03% sodium carboxymethyl cellulose and were administered orally immediately after infection. ED 50 values were determined by the Litchfield-Wilcoxon method according to the mortality of mice at 7 days after infection. The survival percentage values were recorded as percentages of the surviving mice (10 mice a group) on doses of 100, 60 and 40 mg/kg at 7 days after infection.
Results
The MIC, ribosome-binding activities (ID 50 ), retention times on HPLC, and therapeutic effects in mice of various kinds of derivatives are shown in Tables I to VI.
4''sulphonates and 4"-alkylethers {Table I)
Any 4"-0-sulphonyl (1 to 7) and 4"-0-alkylspiramycin I (8 to 11) showed lower MIC values than that of spiramycin I. The ID 50 values of sulphonates were comparable to, and those of alkylethers somewhat higher than, that of spiramycin I. The ED 50 values of mesyl (1) and ethanesulphonyl (2) derivatives were similar to that of spiramycin I, but benzylsulphonyl (4) and />-toluenesulphonyl (5) derivatives having long retention times showed the higher ones. 4"-O-Ethylspiramycin I (9) was equally effective against Str. pneumoniae III infection but less active against Staph. aureus Smith infection.
3" ', 3", The MIC of the derivatives of this group against Staph. aureus were 1-56 to 6-25 mg/1. (28) (31) were comparable to that of spiramycin I but the others were less effective. In terms of survival percentage, the diacylates were more effective than spiramycin I. 3"-O-Propionyl-4"-O-acetyl (16), 3",4"-di-O-propionyl (17), 3"-0-propionyl-4"-C>-butyrylspiramycin I (18) and all the triacylates were almost comparable to acetylspiramycin. It was notable that 3,3",4"-tri-0-propionyl (31) and 3,4"-di-O-acetyl-3"-C>-butyrylspiramycin I (33) showed higher therapeutic effects than acetylspiramycin.
The retention time values increased with an increase in the length of alkyl chain of the 3"-and 4"-acyl groups but 3-acyl groups scarcely affected the retention time.
4"'-De-N-methylspiramycin I and the derivatives {Table III)
These derivatives had MIC of 3-12 to 25 mg/1 against Staph. aureus, and were more active compared with 3' derivatives. 4"'-Af-Fmoc-Gly (39) and 4"'-A^-benzyl derivatives (41), substituted with the rather lipophilic groups, had similar MIC to those of spiramycin I. The ID 50 values were parallel with MIC, except for 4"'-A^-glycyl (40) and 4'"-dimethylcarbamoyl derivatives (42).
And/or 4'-acetal derivatives of neospiramycin I {Table IV)
Among tetrahydrofuranyl derivatives of neospiramycin I, the derivatives with aconfiguration were more active than those with ^-configuration, and 3,4'-di-Otetrahydrofuranyl derivatives were more active in vivo than mono-substituted ones. The absolute configuration of C-1 of tetrahydrofuranyl and tetrahydropyranyl groups could not be determined and we have called one configuration a and the other b. It is worth noting that the most active derivatives in this series is 3-a-4'-a-di-O-tetrahydrofuranylneospiramycin I (52) with a similar therapeutic effect to that of spiramycin I. In the 4'-position the tetrahydropyranyl derivatives with the a-configuration is more active in vitro than those with b. However, in the 3-position the derivative with thê -configuration is more effective.
4'-Deoxyneospiramycin I derivatives {Table V)
Among these derivatives, 12-(8)-4'-deoxyneospiramycin I (64) bearing a 3-hydroxy group, was the most active in vitro. The 12Z isomers were more active than the corresponding natural 12.E isomers, in spite of the lower affinity to ribosomes. The 12Z isomers had a slightly shorter retention time.
Chimeramycins A and B {Table VI)
Chimeramycins A (67) and B (68) were as active in vitro as spiramycin I and tylosin, respectively.
Discussion
There are many factors to be taken into consideration for the evaluation of in vivo antibiotic activity. We have determined the MIC, ID 60 , retention time and therapeutic effects of spiramycin derivatives. Since it is known that the binding of a macrolide to the 50 s subunit of a bacterial ribosome causes inhibition of protein synthesis (Corcoran, 1971; Oleinick, 1975) , the ID 50 value for ribosome binding is one of the parameters for the evaluation of derivatives at the level of the bacterial target. It is possible to assess the change of permeability of the cell membrane by the comparison of ID 50 and MIC . The retention time in HPLC with a reverse phase system, shows lipophilicity (Brent et al., 1983) which is one of the factors that determine the pharmacokinetics such as absorption and distribution. The therapeutic effect would appear as a result of the combination of these factors.
The MIC values of spiramycin I derivatives are not affected by the substituents on the 4"-position regardless of their bulk, as shown in 4"-sulphonates and alkylethers. On the other hand, when the 3"-hydroxy group is simultaneously substituted, the combination of the substituents becomes important for MIC and therapeutic effect, as in the case of the 3",4"-diacylates and 3,3",4"-triacylates, indicating that the stereochemistry around the 3"-and 4"-positions is restricted. The stereochemistry of the 3-and 4'-positions is also highly restricted and an inadequate conformation of the substituents depress antimicrobial activity and therapeutic effect as shown in the acetal derivatives of neospiramycin I. 4"'-N-Substituted derivatives of 4"'-de-Af-methylspiramycin I and 12Z isomers of neospiramycin I show similar antimicrobial activities to that of spiramycin I. Naturally-occurring 16-membered macrolides such as leucomycins, tylosin and angolamycin, which are differentiated in the structure at 9-, 12-and 13-positions from spiramycin I, are known to have similar antibacterial activities to that of spiramycin I. These facts suggest that the bulk tolerance exists around the left side of the lactone of these macrolide antibiotics.
12Z Derivatives of neospiramycin I are effective in antimicrobial activity in spite of their low affinities to ribosomes, showing that the conformational change in the aglycone moiety derived from the geometrical isomerism at the 12-position results in a higher permeability into bacterial cells. On the other hand, the introduction of a hydrophilic group to the 4'"-position depresses the permeability.
The introduction of acyl group to the 3"-position affects permeability into bacterial The configurations of the THF group on the 3-and 4'-positions affect ED 50 values, correlating with MIC. The 4'-0-THF group appear to contribute to an increase of in-vitro and in-vivo activity to a greater extent than that on 3-position. Although neospiramycin has greater in-vitro antibacterial activity than spiramycin (Takahira, 1970; Paul & Tchlitcheff, 1957) , it is almost inactive in vivo. The evidence that 3-a-4'-a-di-Otetrahydrofuranylneospiramycin I (52) shows a similar therapeutic effect to that of spiramycin I implies that the pharmacokinetics of neospiramycin I are improved by the introduction of the THF group, suggesting the direction for improvement of the in-vivo activity of neospiramycin.
Therapeutic effects of 4"-0-substituted derivatives bearing relatively small sulphonyl and alkyl groups are comparable to that of spiramycin I whereas those of derivatives with a more bulky group are weak. The ED 50 values almost correlate with the retention times values.
Drawing the four parameters of a derivative in a graph is a useful way to understand the characteristics of the compound. Figure 1 shows the graphs for spiramycin I and its acyl derivatives in which a propionyl group is introduced to 3"-position. The relationships between retention time or MIC, and size of acyl group can be understood from these graphs. In therapeutic effect, indicated by survival percentage, the first three derivatives (16, 17, 18) are equivalent to each other, whereas the /-valeryl derivative (19) shows a weaker one. When the third propionyl group is introduced to the 3-position of 3",4"-dipropionate (17), the survival percentage is significantly increased though the MIC is not changed, as shown in the last graph. These findings would indicate that the pharmacological characteristics such as absorption, distribution and metabolism of these derivatives affect therapeutic activity considerably and that the introduction of acyl groups of a suitable size to the 3-and 3"-positions is highly effective in terms of therapeutic effects. The property of the whole molecule arising from the combination of 3"-and 4"-, or 3-, 3"-and 4"-substituents is important for the therapeutic effect, and it is difficult to discuss each substituent separately. During our screening of the derivatives of spiramycin, 3,3",4"-tri-0-propionyl-(31) and 3,4"-di-0-acetyl-3"-O-butyrylspiramycin I (33) were found to be the most effective in vivo and to be superior to acetylspiramycin. 
